{
    "address": "Venlighedsvej 1",
    "city": "Hoersholm",
    "country": "DK",
    "currency": "DKK",
    "cusip": "K0329P106",
    "description": "Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. The firm s current priority program focus is on the advancement of three precision medicine treatments: 2X-121, Dovitinib and Ixempra targeting the market for the treatment of ovarian cancer, breast cancer, and renal cell carcinoma.",
    "employeeTotal": "14.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2013-10-04",
    "isin": "DK0060732477",
    "logo": "",
    "marketCapitalization": 361.8413,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Allarity Therapeutics A/S",
    "phone": "4588742414.0",
    "sedol": "BD8CXN2",
    "shareOutstanding": 361.303073,
    "state": "",
    "ticker": "ALLR.ST",
    "weburl": "https://allarity.com/"
}